ライフサイエンスコーパス: portal pressure

1 Both TIPS and HGPCS reduced portal pressure.

2 nsation in cirrhosis, possibly by increasing portal pressure.

3 is extent (hydroxyproline concentration) and portal pressure.

4 on by IFX was associated with a reduction in portal pressure.

5 nic blood flow, portohepatic resistance, and portal pressure.

6 clude bleeding, thrombosis, and elevation of portal pressure.

7 horylation and NO production, and normalized portal pressure.

8 duced the elevated mesenteric blood flow and portal pressure.

9 ficantly reduced intrahepatic resistance and portal pressure.

10 -L-arginine reduced NO release and increased portal pressure.

11 rowth factor) without significant changes in portal pressure.

12 endogenous endothelial-derived NO modulates portal pressure.

13 ute to increased intrahepatic resistance and portal pressure.

14 mol/L) caused a rapid and pronounced rise in portal pressure.

15 , animals with hepatic fibrosis had a higher portal pressure (13.0 +/- 3.6 vs. 3.7 +/- 1.4 mm Hg, P <

16 Reduction of elevated portal pressure after 80% PH by terlipressin was associa

17 ould be used sparingly because they increase portal pressure and carry a risk of transfusion-associat

18 trahepatic portosystemic shunts (TIPS) lower portal pressure and have been used in the treatment of r

19 s blood flow (PVBF) has been shown to reduce portal pressure and intrahepatic vascular resistance and

20 NE(-/-) and Pad4(-/-) mice had lower portal pressure and livers had less fibrin compared with

21 etic resonance elastography, correlated with portal pressure and preceded fibrosis in our model.

22 nselective beta-adrenergic blockers decrease portal pressure and prevent variceal hemorrhage.

23 rial and portal blood flow, without changing portal pressure and renal blood flow.

24 actor (vWF) antigen (vWF-Ag) correlates with portal pressure and seems capable of predicting complica

25 acute and chronic JWH-015 treatment reduced portal pressure and superior mesenteric arterial blood f

26 Nonselective beta blockers (NSBBs) reduce portal pressure and the risk for variceal hemorrhage in

27 ative causes of EAD after LDLT are excessive portal pressure and/or flow.

28 define prospectively the effects of TIPS on portal pressures and flow, variceal resolution, and hepa

29 Each procedure significantly reduced portal pressures and portasystemic pressure gradients.

30 Liver fibrosis, portal pressure, and hepatic tumor burden in BALB/c.Mdr2

31 n, plasma renin, cardiocirculatory function, portal pressure, and plasma levels of cytokines, collect

32 Mean arterial pressure, portal pressure, and SMA blood flow were measured by cat

33 tance was calculated from arterial pressure, portal pressure, and SMA flow.

34 ion were attenuated based on immunostaining, portal pressure, and spleen/body weight ratio.

35 rhotic nodules correlated independently with portal pressure (as determined by the hepatic venous pre

36 Alcoholic hepatitis patients have higher portal pressures associated with increased ADMA, which m

37 (by 72%), serum ammonia levels (by 46%), and portal pressure (average 6.07 vs. 8.53 mm Hg in controls

38 adient (HVPG) is the standard for estimating portal pressure but requires expertise for interpretatio

39 re associated with infused islet volumes and portal pressures but not platelet counts or other measur

40 nsated cirrhosis, exercise acutely increases portal pressure, but in the longer term it has been prov

41 rogate endpoint for interventions that lower portal pressure by decreasing intrahepatic resistance.

42 R downstream signaling pathway and decreased portal pressure by lowering total IHVR without deleterio

43 nto sinusoidal lumen of liver might increase portal pressure by promoting sinusoid microthrombi.

44 Mean arterial pressure, portal pressure, cardiac output, total peripheral resist

45 rtension (PHT) is characterized by increased portal pressure caused in part by a reduction in mesente

46 nchnic blood flow contribute to the elevated portal pressure characteristic of PHT.

47 significantly reduced portal blood flow and portal pressure compared to vehicle (13.6 +/- 5.7 versus

48 Additionally, an increase in portal pressure concomitant with the blockade of NO rele

49 invasive liver disease assessments to assess portal pressure, especially clinically significant porta

50 rahepatic portasystemic stent shunts reduced portal pressures from 32 +/- 7.5 mmHg (standard deviatio

51 sion index (HPi)," defined as posttransplant portal pressure gradient (DeltaPpost)/graft-to-recipient

52 as to determine the optimal reduction of the portal pressure gradient (PPG) through TIPS to control a

53 BACKGROUND & AIMS: A reduction in portal pressure gradient (PPG) to <12 mm Hg after placem

54 n was improved by TIPS in all patients (mean portal pressure gradient before TIPS, 20.2 +/- 4.6 vs. 6

55 The portal pressure gradient was determined based on HVPG at

56 syndrome characterized by an increase in the portal pressure gradient, defined as the gradient betwee

57 Within the first 5 days, the portal-pressure gradient increased significantly in pati

58 l flow in animals with hepatic fibrosis, the portal pressure greatly reduced (13.0 +/- 3.6 to 2.5 +/-

59 effective than traditional NSBBs in reducing portal pressure hepatic venous pressure gradient (HVPG).

60 he lipid-lowering drug simvastatin decreases portal pressure, improves hepatocellular function, and m

61 Modulation lowered portal pressure in 68% of subjects with inconsistent eff

62 IRL 1620 (an ET(B) agonist) increased portal pressure in a dose-dependent manner, and the incr

63 Terutroban reduced portal pressure in both models without producing signifi

64 -receptor blockade with terutroban decreases portal pressure in cirrhosis.

65 c oxide (NO) donor, has been shown to reduce portal pressure in cirrhotic patients.

66 derate exercise were safe and reduced BW and portal pressure in overweight/obese patients with cirrho

67 ced a selective and significant reduction in portal pressure in pathologically distinct PHT models, t

68 Statins decrease portal pressure in patients with cirrhosis and increase

69 d ETB receptor antagonist, bosentan, reduced portal pressure in portal hypertensive animals, consiste

70 tion of Akt and production of NO and reduced portal pressure in portal hypertensive rats.

71 the hyperdynamic circulation, and decreases portal pressure in PVL-operated rats.

72 wn mediators of stellate cell contraction on portal pressure in rat livers after carbon tetrachloride

73 blocker, decreases hepatic vascular tone and portal pressure in rats with cirrhosis due to carbon tet

74 s contributes to the maintenance of elevated portal pressure in these animals.

75 s with cirrhosis, and if weight loss reduces portal pressure in this setting, is unknown.

76 reatment of portal hypertension would reduce portal pressure, increase renal blood flow, and produce

77 Portal pressure increased from about 3 to 10.5 cm H2O up

78 During volume expansion, similar portal pressure increases were observed in CIH and HC ra

79 MasR blockade reduced portal pressure, indicating that activation of this rece

80 Portal pressure is estimated in practice by the HVPG.

81 HVPG, a surrogate of portal pressure, is the reference standard test to asses

82 thrombin generation, and adverse effects on portal pressure limit the utility of this agent signific

83 esized that vWF-Ag levels may correlate with portal pressure, measured by hepatic venous pressure gra

84 The effects of sedatives on portal pressure measurements have not yet been defined.

85 should be assessed by venography and direct portal pressure measurements until a more reliable and p

86 Portal pressure measurements were elevated in 2 patients

87 Reduction of elevated portal pressure post-PH by the use of terlipressin impro

88 05) and significantly attenuated the rise in portal pressure (PP) (12.7 +/- 0.8 vs. 15.2 +/- 0.5 mm H

89 erformed hemodynamic measurements, including portal pressure (PP) and portosystemic shunts (PSS), and

90 patic collagen proportionate area (CPA) with portal pressure (PP) in animals or HVPG in patients.

91 RVXB significantly decreased portal pressure (PP) in both models of cirrhosis without

92 stomach lumen increases splanchnic flow and portal pressure (PP) in portal-hypertensive rats.

93 tion have shown their usefulness in reducing portal pressure (PP) in this condition.

94 Monitoring the hemodynamic response of portal pressure (PP) to drug therapy accurately stratifi

95 reased systemic vascular resistance, reduced portal pressure (PP), superior mesenteric artery flow, m

96 cardiac output lead to a further increase in portal pressure (PP).

97 IPS) (8 mm; n = 90), or medical reduction of portal pressure (propranolol and isosorbide-5-mononitrat

98 plus simvastatin significantly enhances the portal pressure reduction achieved with carvedilol monot

99 rdynamic circulation and significantly lower portal pressure reduction after acute beta-blockade than

100 examine splanchnic vascular hemodynamics and portal pressure response.

101 Atorvastatin decreased portal pressure, shunt flow and angiogenesis in cirrhosi

102 local inflammatory reaction and increase in portal pressure, threatening islet survival and potentia

103 l infection results in a further increase in portal pressure through the induction of endothelin and

104 vascular resistance and significantly lower portal pressure, TNF plasma levels, and 24-hour urinary

105 e activity, indocyanine green secretion, and portal pressure values were determined at major time poi

106 Vasoconstrictors reduce portal pressure via splanchnic vasoconstriction and are

107 Mean portal pressure was dropped from 33.08 +/- 1.38 mmHg pre

108 Portal pressure was measured to test whether Nogo-B gene

109 Portal pressure was measured using a digital blood press

110 rols (P = 0.03), whereas such an increase in portal pressure was not observed in NGB KO mice (P = NS)

111 Four weeks after BDL, portal pressure was significantly increased in WT mice b

112 Necroinflammation, fibrosis, and portal pressure were either histologically scored or bio

113 potent stellate cell contractile agonist) on portal pressure were greater in cirrhotic than normal li

114 Transient elevations of the portal pressure were observed during cell infusion.

115 Hepatic fibrosis and portal pressure were significantly increased after pIVCL

116 ery blood flow, and systemic, pulmonary, and portal pressures were measured.

117 vers, which correlated with the reduction in portal pressure when compared with simple cold storage (

118 (ETB) receptor agonist, had minor effects on portal pressure when perfused into normal livers at conc